Cargando…

Dengvaxia: the world’s first vaccine for prevention of secondary dengue

The objective of this manuscript was to review and evaluate the efficacy and safety data of Dengvaxia for the treatment of severe secondary dengue infection. Dengvaxia is the brand name for chimeric yellow fever-dengue-tetravalent dengue vaccine (CYD-TDV). A literature search through PubMed was cond...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tully, Danielle, Griffiths, Carrie L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132086/ https://www.ncbi.nlm.nih.gov/pubmed/34036241 http://dx.doi.org/10.1177/25151355211015839

Ejemplares similares

Does structurally-mature dengue virion matter in vaccine preparation in post-Dengvaxia era?
por: Galula, Jedhan Ucat, et al.
Publicado: (2019)

Dengvaxia controversy: impact on vaccine hesitancy
por: Fatima, Khunsha, et al.
Publicado: (2018)

Estimating the proportion of vaccine-induced hospitalized dengue cases among Dengvaxia vaccinees in the Philippines
por: Flasche, Stefan, et al.
Publicado: (2019)

A review of Dengvaxia®: development to deployment
por: Thomas, Stephen J., et al.
Publicado: (2019)

Consumer Willingness to Pay for Dengue Vaccine (CYD-TDV, Dengvaxia(®)) in Brazil; Implications for Future Pricing Considerations
por: Godói, Isabella P., et al.
Publicado: (2017)

Identification of prior dengue-naïve Dengvaxia recipients with an increased risk for symptomatic dengue during fever surveillance in the Philippines
por: Dai, Yu-Ching, et al.
Publicado: (2023)

The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study
por: Flasche, Stefan, et al.
Publicado: (2016)

Projected costs associated with school-based screening to inform deployment of Dengvaxia: Vietnam as a case study
por: Turner, Hugo C, et al.
Publicado: (2018)

A cross‐sectional survey to evaluate prescribers' knowledge and understanding of safety messages following Dengvaxia® product information update
por: Almas, Mariana F., et al.
Publicado: (2022)

Vaccines and immunization strategies for dengue prevention
por: Liu, Yang, et al.
Publicado: (2016)

Dengue: a growing threat requiring vaccine development for disease prevention
por: Bos, Sandra, et al.
Publicado: (2018)

The Effect of E-Learning on the Attitude Toward Dengue Prevention and the Acceptance of Dengue Vaccination
por: Ali, Mohammad, et al.
Publicado: (2021)

Efficacy of Dengue Vaccines in the Prevention of Severe Dengue in Children: A Systematic Review
por: Foucambert, Paul, et al.
Publicado: (2022)

Current progress in dengue vaccines
por: Wan, Shu-Wen, et al.
Publicado: (2013)

Human antibody response to dengue virus: implications for dengue vaccine design
por: Moi, Meng Ling, et al.
Publicado: (2016)

Serological inference of past primary and secondary dengue infection: implications for vaccination
por: Lam, Ha Minh, et al.
Publicado: (2019)

A Review on Dengue Vaccine Development
por: Deng, Sheng-Qun, et al.
Publicado: (2020)

‘Mix and Match’ vaccination: Is dengue next?
por: Odio, Camila D., et al.
Publicado: (2022)

A dengue vaccine whirlwind update
por: Kariyawasam, Ruwandi, et al.
Publicado: (2023)

Non-Human Primate Models of Dengue Virus Infection: A Comparison of Viremia Levels and Antibody Responses during Primary and Secondary Infection among Old World and New World Monkeys
por: Muhammad Azami, Nor Azila, et al.
Publicado: (2020)

A Critical Assessment of Vector Control for Dengue Prevention
por: Achee, Nicole L., et al.
Publicado: (2015)

Trends in clinical trials of dengue vaccine
por: Marimuthu, Priya, et al.
Publicado: (2016)

Household costs of dengue illness: secondary outcomes from a randomised controlled trial of dengue prevention in Guerrero state, Mexico
por: Legorreta-Soberanis, José, et al.
Publicado: (2017)

Issues Related to Recent Dengue Vaccine Development
por: Konishi, Eiji
Publicado: (2011)

Dengue seroprevalence: data from the clinical development of a tetravalent dengue vaccine in 14 countries (2005–2014)
por: L’Azou, Maïna, et al.
Publicado: (2018)

Updates on Dengue Vaccine and Antiviral: Where Are We Heading?
por: Norshidah, Harun, et al.
Publicado: (2021)

Implications of Discordance in World Health Organization 1997 and 2009 Dengue Classifications in Adult Dengue
por: Gan, Victor C., et al.
Publicado: (2013)

Nucleic Acid Vaccine Platform for DENGUE and ZIKA Flaviviruses
por: Taslem Mourosi, Jarin, et al.
Publicado: (2022)

Preparedness for the Dengue Epidemic: Vaccine as a Viable Approach
por: Zeyaullah, Md., et al.
Publicado: (2022)

Dengue Fever: Causes, Complications, and Vaccine Strategies
por: Khetarpal, Niyati, et al.
Publicado: (2016)

Animal models for dengue vaccine development and testing
por: Na, Woonsung, et al.
Publicado: (2017)

Dengue Vaccines: An Update
por: Torres-Flores, Jesús M., et al.
Publicado: (2022)

Safety of Dengue Vaccine?
por: Biswal, Shibadas, et al.
Publicado: (2022)

SIR Model for Dengue Disease with Effect of Dengue Vaccination
por: Chanprasopchai, Pratchaya, et al.
Publicado: (2018)

Controlling Dengue with Vaccines in Thailand
por: Chao, Dennis L., et al.
Publicado: (2012)

Secondary Analysis of the Efficacy and Safety Trial Data of the Tetravalent Dengue Vaccine in Children and Adolescents in Colombia
por: Reynales, Humberto, et al.
Publicado: (2020)

Phase 1 trial to model primary, secondary, and tertiary dengue using a monovalent vaccine
por: Odio, Camila D., et al.
Publicado: (2023)

World Dengue Day: A call for action
por: Srisawat, Nattachai, et al.
Publicado: (2022)

In silico prediction of monovalent and chimeric tetravalent vaccines for prevention and treatment of dengue fever
por: Subramaniyan, Vijayakumar, et al.
Publicado: (2018)

Impact of Dengue Vaccination on Serological Diagnosis: Insights From Phase III Dengue Vaccine Efficacy Trials
por: Plennevaux, Eric, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_a79n3sso979sfvsaolqu5lvp4f